These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 7693814)

  • 21. Human basophil releasability. I. Age-related changes in basophil releasability.
    Marone G; Poto S; di Martino L; Condorelli M
    J Allergy Clin Immunol; 1986 Feb; 77(2):377-83. PubMed ID: 2418093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced IgE-dependent basophil histamine release and airway reactivity in asthma.
    Gaddy JN; Busse WW
    Am Rev Respir Dis; 1986 Nov; 134(5):969-74. PubMed ID: 3096179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Altered surface expression of CD11 and Leu 8 during human basophil degranulation.
    Bochner BS; Sterbinsky SA
    J Immunol; 1991 Apr; 146(7):2367-73. PubMed ID: 1706397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of mechanisms of IL-3 induced histamine release and IL-3 priming effect on human basophils.
    Okayama Y; Begishvili TB; Church MK
    Clin Exp Allergy; 1993 Nov; 23(11):901-10. PubMed ID: 10779277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of pertussis toxin on mediator release from human basophils.
    Warner JA; Yancey KB; MacGlashan DW
    J Immunol; 1987 Jul; 139(1):161-5. PubMed ID: 2438348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of interleukin 2 on basophil histamine release.
    Morita Y; Goto M; Miyamoto T
    Allergy; 1987 Feb; 42(2):104-8. PubMed ID: 2438959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Basophil histamine release decreases during omalizumab therapy in allergic asthmatics.
    Noga O; Hanf G; Kunkel G; Kleine-Tebbe J
    Int Arch Allergy Immunol; 2008; 146(1):66-70. PubMed ID: 18087163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of histamine release from human basophils in vitro by physiological concentrations of zinc.
    Marone G; Findlay SR; Lichtenstein LM
    J Pharmacol Exp Ther; 1981 May; 217(2):292-8. PubMed ID: 6164779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of human basophil histamine release by hemopoietic growth factors.
    Hirai K; Morita Y; Misaki Y; Ohta K; Takaishi T; Suzuki S; Motoyoshi K; Miyamoto T
    J Immunol; 1988 Dec; 141(11):3958-64. PubMed ID: 2460553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of interleukin 3 upon IgE-dependent and IgE-independent basophil degranulation and leukotriene generation.
    Kurimoto Y; De Weck AL; Dahinden CA
    Eur J Immunol; 1991 Feb; 21(2):361-8. PubMed ID: 1705512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Studies on human basophil releasability.
    Marone G; Poto S; Giugliano R; Bonini S
    Int Arch Allergy Appl Immunol; 1985; 77(1-2):103-6. PubMed ID: 2409008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-inflammatory effects of glucocorticoids and cyclosporin A on human basophils.
    Marone G; Stellato C; Renda A; Genovese A
    Eur J Clin Pharmacol; 1993; 45 Suppl 1():S17-20; discussion S43-4. PubMed ID: 7508864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of basophil histamine release by anti-inflammatory steroids. II. Studies on the mechanism of action.
    Schleimer RP; MacGlashan DW; Gillespie E; Lichtenstein LM
    J Immunol; 1982 Oct; 129(4):1632-6. PubMed ID: 6180017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characteristics of human basophil sulfidopeptide leukotriene release: releasability defined as the ability of the basophil to respond to dimeric cross-links.
    MacGlashan DW; Peters SP; Warner J; Lichtenstein LM
    J Immunol; 1986 Mar; 136(6):2231-9. PubMed ID: 2419427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils.
    Zuberbier T; Chong SU; Grunow K; Guhl S; Welker P; Grassberger M; Henz BM
    J Allergy Clin Immunol; 2001 Aug; 108(2):275-80. PubMed ID: 11496246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endogenous superallergen protein Fv induces IL-4 secretion from human Fc epsilon RI+ cells through interaction with the VH3 region of IgE.
    Patella V; Giuliano A; Bouvet JP; Marone G
    J Immunol; 1998 Nov; 161(10):5647-55. PubMed ID: 9820545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Basophil releasability in patients with hymenoptera venom allergy.
    Radermecker MF; Leclercq MD; Mariz SD; Louis RE
    Int Arch Allergy Immunol; 1993; 101(3):283-7. PubMed ID: 7686798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measurement of IgE on human basophils: relation to serum IgE and anti-IgE-induced histamine release.
    Conroy MC; Adkinson NF; lichtenstein LM
    J Immunol; 1977 Apr; 118(4):1317-21. PubMed ID: 66288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platelet-activating factor induces mediator release by human basophils primed with IL-3, granulocyte-macrophage colony-stimulating factor, or IL-5.
    Brunner T; de Weck AL; Dahinden CA
    J Immunol; 1991 Jul; 147(1):237-42. PubMed ID: 1711077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The mechanism of mediator release from human basophils induced by platelet-activating factor.
    Columbo M; Casolaro V; Warner JA; MacGlashan DW; Kagey-Sobotka A; Lichtenstein LM
    J Immunol; 1990 Dec; 145(11):3855-61. PubMed ID: 1700998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.